These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30247183)

  • 1. Outcome of High-risk Langerhans Cell Histiocytosis (LCH) in Egyptian Children, Does Intermediate-dose Methotrexate Improve the Outcome?
    Sedky MS; Hamouda A; Taha H; Zaky I; Hassanain O; El Hemaly A; ElHaddad A
    J Pediatr Hematol Oncol; 2019 Nov; 41(8):635-643. PubMed ID: 30247183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High risk Langerhans cell histiocytosis in children: the role of salvage in improving the outcome. A single center experience.
    Sedky MSM; Hamoda A; Taha H; Zaky I; Hassanain O; ElHaddad A
    Orphanet J Rare Dis; 2024 Jun; 19(1):242. PubMed ID: 38910253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
    Gadner H; Minkov M; Grois N; Pötschger U; Thiem E; Aricò M; Astigarraga I; Braier J; Donadieu J; Henter JI; Janka-Schaub G; McClain KL; Weitzman S; Windebank K; Ladisch S;
    Blood; 2013 Jun; 121(25):5006-14. PubMed ID: 23589673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Langerhans Cell Histiocytosis (LCH) in Egyptian Children: Does Reactivation Affect the Outcome?
    Sedky MS; Rahman HA; Moussa E; Taha H; Raafat T; Hassanein O
    Indian J Pediatr; 2016 Mar; 83(3):214-9. PubMed ID: 26133729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
    Narula G; Pradhan ND; Arora B; Banavali SD
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates.
    Tantawy AAG; Ragab IA; Elsherif NHK; Makkeyah SM; AbdelRaheem HG; Elsantiel HIE
    Pediatr Hematol Oncol; 2020 Nov; 37(8):696-706. PubMed ID: 32706277
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical manifestations of Langerhans cell histiocytosis with multisystem involvement in 53 children].
    Tang JJ; Xu XJ; Wang YC; Bai ST; Wang L; Ni XL; Liu YF
    Zhonghua Er Ke Za Zhi; 2021 Jan; 59(1):37-41. PubMed ID: 33397002
    [No Abstract]   [Full Text] [Related]  

  • 8. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kawaguchi H; Sakashita K; Yasui M; Koga Y; Kobayashi R; Ishii E; Fujimoto J; Horibe K; Bessho F; Tsunematsu Y; Imashuku S
    Int J Hematol; 2016 Jul; 104(1):99-109. PubMed ID: 27040279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group.
    Gadner H; Heitger A; Grois N; Gatterer-Menz I; Ladisch S
    Med Pediatr Oncol; 1994; 23(2):72-80. PubMed ID: 8202045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of children with Langerhans cell histiocytosis and single-system involvement: A retrospective study at a single center in Shanghai, China.
    Su M; Gao YJ; Pan C; Chen J; Tang JY
    Pediatr Hematol Oncol; 2018; 35(7-8):385-392. PubMed ID: 30693828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone.
    Wang W; Ge J; Ma H; Lian H; Cui L; Zhao Y; Li Z; Wang T; Zhang R
    BMC Pediatr; 2024 Jan; 24(1):1. PubMed ID: 38172736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.
    Minkov M
    Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study.
    Tazi A; Lorillon G; Haroche J; Neel A; Dominique S; Aouba A; Bouaziz JD; de Margerie-Melon C; Bugnet E; Cottin V; Comont T; Lavigne C; Kahn JE; Donadieu J; Chevret S
    Orphanet J Rare Dis; 2017 May; 12(1):95. PubMed ID: 28532436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and treatment outcome of Langerhans cell histiocytosis: 22 years' experience of 154 patients at a single center.
    Lee JW; Shin HY; Kang HJ; Kim H; Park JD; Park KD; Kim HS; Park SH; Wang KC; Ahn HS
    Pediatr Hematol Oncol; 2014 Apr; 31(3):293-302. PubMed ID: 24397251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric pulmonary multisystem langerhans cell histiocytosis: does lung lesion severity affect the outcome?
    Sedky M; Gohar S; Ahmed S; Zaky I; Salama A; Hassanein O; Maher E; ElHaddad A
    Orphanet J Rare Dis; 2023 Nov; 18(1):361. PubMed ID: 37978394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kitoh T; Kawaguchi H; Goto H; Kosaka Y; Tsunematsu Y; Imashuku S;
    Int J Hematol; 2018 Aug; 108(2):192-198. PubMed ID: 29594922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management and Outcome of Patients With Langerhans Cell Histiocytosis and Single-Bone CNS-Risk Lesions: A Multi-Institutional Retrospective Study.
    Chellapandian D; Shaikh F; van den Bos C; Somers GR; Astigarraga I; Jubran R; Degar B; Carret AS; Mandel K; Belletrutti M; Dix D; Visser J; Abuhadra N; Chang T; Rollins B; Whitlock J; Weitzman S; Abla O
    Pediatr Blood Cancer; 2015 Dec; 62(12):2162-6. PubMed ID: 26179251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective study.
    Ng Wing Tin S; Martin-Duverneuil N; Idbaih A; Garel C; Ribeiro M; Parker JL; Defachelles AS; Lambilliotte A; Barkaoui M; Munzer M; Gardembas M; Sibilia J; Lutz P; Fior R; Polak M; Robert A; Aumaitre O; Plantaz D; Armari-Alla C; Genereau T; Berard PM; Talom GN; Pennaforte JL; Le Pointe HD; Barthez MA; Couillault G; Haroche J; Mokhtari K; Donadieu J; Hoang-Xuan K;
    Orphanet J Rare Dis; 2011 Dec; 6():83. PubMed ID: 22151964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.